Orforglipron (brand name Foundayo) and oral Wegovy (oral semaglutide 25 mg) are the first two prescription weight-loss pills approved in the US, and they take different routes to the same goal. Oral semaglutide produced slightly more weight loss in trials, around 13.6% versus about 12.4% for orforglipron, but orforglipron is far easier to take, with no food or water rules. Both cause mostly gastrointestinal side effects. Neither is sold by TrimRx, which prescribes injectable semaglutide and tirzepatide, so if a pill isn’t a must, injections remain the stronger choice. Here’s the comparison.<\/p>\n
The biggest difference is not the results, it’s the daily routine each one demands. Oral semaglutide is the same molecule as the Wegovy injection, but peptides like semaglutide break down easily in the stomach. To get absorbed, the pill has to be taken first thing in the morning on an empty stomach with no more than a few sips of water, followed by a 30-minute wait before eating, drinking, or taking anything else.<\/p>\n
Orforglipron is built differently. It’s a small-molecule GLP-1, which is far more stable in the gut, so it can be taken any time of day, with or without food, and without the water restriction. For anyone whose mornings are unpredictable, that flexibility is a genuine advantage.<\/p>\n
The efficacy gap is small. In the OASIS 4 trial<\/a> published in the New England Journal of Medicine in 2025, oral semaglutide 25 mg produced roughly 13.6% average weight loss over 64 weeks. Orforglipron reached about 12.4% at its highest dose in its own trials. So oral semaglutide edges ahead on paper, though both land below what the injectable versions deliver.<\/p>\n Both drugs share the GLP-1 side effect profile, mainly nausea, constipation, and diarrhea that tend to ease as the dose rises. Orforglipron also lists headache and fatigue, and it carries a boxed warning about a rare thyroid tumor risk seen in animal studies, which is a class-wide caution for these medications. Oral semaglutide’s strict timing is its own hurdle, since a rushed morning can mean lower absorption or a skipped dose.<\/p>\n Consider a hypothetical patient who travels often and eats breakfast at unpredictable times. The empty-stomach routine would be a constant headache for him, so orforglipron’s flexibility likely matters more than the small efficacy difference. Someone who keeps a steady morning routine and wants the most weight loss from a pill might lean toward oral semaglutide instead.<\/p>\n One point worth being clear about: neither pill is available through TrimRx. Both are sold through their manufacturers by prescription. TrimRx prescribes injectable semaglutide and tirzepatide, in compounded and brand-name forms, and those injections produce more weight loss (roughly 15% to 21% in trials) than either pill. If you’re open to a weekly injection rather than a daily tablet, that’s the more effective path, and you can explore the options available to you now through the TrimRx quiz<\/a>.<\/p>\n Oral semaglutide showed slightly more weight loss in trials (about 13.6% versus 12.4%), but the difference is modest. Both pills produce less weight loss than injectable semaglutide or tirzepatide, so the pill choice is more about convenience than maximum results.<\/p>\n No. Both orforglipron and oral Wegovy are available through their manufacturers by prescription. TrimRx prescribes injectable semaglutide and tirzepatide, which remain the more effective options.<\/p>\n Semaglutide is a peptide that degrades in the stomach, so it needs an empty stomach and a special absorption enhancer to work. Food or too much water interferes with how much gets into your system, which is why the timing is so specific.<\/p>\n\n\n
\n \nFeature<\/th>\n Orforglipron (Foundayo)<\/th>\n Oral Wegovy (oral semaglutide 25 mg)<\/th>\n<\/tr>\n<\/thead>\n \n Type<\/td>\n Small-molecule GLP-1 pill<\/td>\n Peptide GLP-1 pill<\/td>\n<\/tr>\n \n Average weight loss<\/td>\n ~12.4%<\/td>\n ~13.6%<\/td>\n<\/tr>\n \n How to take<\/td>\n Any time, with or without food<\/td>\n Empty stomach, small sip of water, wait 30 minutes<\/td>\n<\/tr>\n \n Approved for obesity<\/td>\n April 2026<\/td>\n December 2025<\/td>\n<\/tr>\n \n Notable cautions<\/td>\n Boxed warning (thyroid), GI, headache, fatigue<\/td>\n GI side effects, strict timing<\/td>\n<\/tr>\n \n Sold by TrimRx<\/td>\n No (through its manufacturer)<\/td>\n No (through its manufacturer)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n Side Effects and Practical Fit<\/h3>\n
Frequently Asked Questions<\/h3>\n
Is orforglipron or oral Wegovy more effective?<\/h4>\n
Can I get these pills through TrimRx?<\/h4>\n
Why does oral semaglutide have such strict timing rules?<\/h4>\n